Involvement of CD74 in head and neck squamous cell carcinomas

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 6, 2014, Pages 937-947

  Kindt, Nadège ^a   Lechien, Jérôme R ^a   Nonclercq, Denis ^a   Laurent, Guy ^a   Saussez, Sven ^a,b  

^a UNIVERSITY OF MONS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

CD74; HNSCC; MIF; Oral carcinoma; SCCVII

Indexed keywords

CD74 ANTIGEN; CRYSTAL VIOLET; GELATINASE B; VASCULOTROPIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOMA CELL; CELL COUNTING; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELLULAR SECRETION; CLINICAL ARTICLE; COHORT ANALYSIS; COLONY FORMATION; CONTROLLED STUDY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROSCOPY; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C3H; MICE, NUDE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901330477     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1648-9     Document Type: Article

References (27)

1. Cheng RJ, Deng WG, Niu CB, Li YY, Fu Y (2011) Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int J Gynecol Cancer 21:1004-1012
2. Choi JW, Kim Y, Lee JH, Kim YS (2013) CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder. Int J Urol 20:251-255
3. Cludts S, Decaestecker C, Johnson B et al (2010) Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res 30:3313-3319
4. França CM, Batista AC, Borra RC et al (2013) Macrophage migration inhibitory factor and oral cancer. J Oral Pathol Med 42:368-373
5. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR (2007) Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther 6:1993-2002 (Pubitemid 47052489)
6. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK (2009) Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol 1:27
7. He XX, Yang J, Ding YW, Liu W, Shen QY, Xia H (2006) Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 55:797-802 (Pubitemid 43764549)
8. Hyams VJ, Batsakis JG, Michaels L (1988) Tumors of the upper respiratory tract and ear. In: Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, DC, pp 123-126
9. Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ (2004) Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br J Cancer 91:1703-1710 (Pubitemid 39546144)
10. Jung H, Seong HA, Ha H (2008) Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem 283:20383-20396
11. Khurana D, Martin EA, Kasperbauer JL et al (2001) Characterization of a spontaneously arising murine squamous cell carcinoma (SCCVII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 23:899-906 (Pubitemid 32862295)
12. Kindt N, Lechien J, Decaestecker C et al (2012) Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res 32:4499-4505
13. Kindt N, Preillon J, Kaltner H et al (2013a) Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol 139:727-737
14. Kindt N, Laurent G, Nonclercq D et al (2013b) Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells. Int J Oncol 43:185-193
15. Krockenberger M, Engel JB, Kolb J et al (2010) Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 136:651-657
16. Leng L, Bucala R (2006) Insight into the biology of macrophage migration inhibitory factor (MIF) revealed by the cloning of its cell surface receptor. Cell Res 16:162-168 (Pubitemid 43247972)
17. Leng L, Metz CN, Fang Y et al (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467-1476 (Pubitemid 36686708)
18. Lue H, Kapurniotu A, Fingerle-Rowson G et al (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18:688-703 (Pubitemid 43113299)
19. Lue H, Thiele M, Franz J et al (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26:5046-5059 (Pubitemid 47206949)
20. McClelland M, Zhao L, Carskadon S, Arenberg D (2009) Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol 174:638-646
21. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177:8730-8739 (Pubitemid 44893839)
22. Molinolo A, Amornphimoltham P, Squarize CH et al (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45:324-334
23. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G (2007) Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle 6:1030-1034 (Pubitemid 46708574)
24. Oda S, Oda T, Nishi K et al (2008) Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One 3:e2215
25. Pries R, Wollenberg B (2006) Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17:141-146 (Pubitemid 43949076)
26. Wang F, Arun P, Friedman J, Chen Z, Van Waes C (2009) Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9:389-395
27. Wittekind C, Greene FL, Hutter RVP (2004) TNM atlas, 5th edn. UICC Springer, Berlin, pp 20-32